EMRUSOLMIN
Dead / Abandoned — Abandoned — express abandonment (as of 30 Jun 2022)
What this means for you
This application is over — abandoned 29 Jun 2022. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.
Record
- Serial number
- 97423939
- Mark type
- Stylized text
- Filed
- 23 May 2022
- Abandoned
- 29 Jun 2022
- Attorney of record
- Timothy J. Maier
Goods and services
- Class 005 — Pharmaceuticals: Medicines for human purposes; Medicines for veterinary purposes; Pharmaceuticals and natural remedies; Medicines for the treatment of Alzheimer's disease; Medicines for the treatment of neurodegenerative diseases; Medicines for the treatment of cardiovascular and cerebrovascular diseases; Chemico-pharmaceutical preparations; Chemical reagents for medical or veterinary purposes; Diagnostic preparations for medical or veterinary purposes; Diagnostic preparations and materials; Diagnostic biomarker reagents for medical purposes; Diagnostic reagents for medical use; Dragees; Injectable pharmaceuticals; Medicinal preparations and substances; Antiparkinson agents; Pharmaceutical drugs; Pharmaceuticals; Pharmaceutical preparations for human use; Pharmaceutical preparations for the treatment of Parkinson's disease; Pharmaceutical preparations for the treatment of Alzeimer's disease; Pharmaceutical preparations for the treatment of neurodegenerative diseases; Pharmaceutical preparations for the treatment of cerebral disease; Pharmaceutical preparations for the treatment of central nervous system diseases
- Class 042 — Scientific and technological services: Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Consultancy relating to pharmaceutical research and development; Biological research, clinical research and medical research; Medical research laboratory services; Testing of pharmaceuticals; Analysis of human serum for medical research; Analysis of human tissues for medical research; Development of pharmaceutical preparations and medicines; Pharmaceutical products development; Research and development of vaccines and medicines; Providing scientific information in the field of medical disorders and their treatment; Research in the field of pharmacogenetics; Research on the subject of pharmaceuticals; Research and development in the pharmaceutical and biotechnology fields; Clinical research; Laboratory research services relating to pharmaceuticals; Medical research; Medical and pharmacological research services; Pharmaceutical drug development services; Pharmaceutical research services; Pharmaceutical research and development; Inspection of pharmaceuticals; Scientific research in the field of pharmacy; Scientific research and development
- Class 044 — Medical, beauty and agricultural services: Medication counseling; Providing information to patients in the field of administering medications; Provision of information relating to pharmaceutical products; Provision of information relating to the treatment of degenerative diseases; Provision of information relating to medical services; Provision of pharmaceutical information; Advisory services relating to the treatment of degenerative diseases; Consultancy and information services relating to pharmaceutical products; Consultancy and information services provided via the Internet relating to pharmaceutical products; Consultancy and information services relating to medical products; Advisory services relating to medicines; Medical services; Medical services for treating Alzheimer's disease; Pharmaceutical services; Preparation and dispensing of medications
Owner
- MODAG GmbH, Wendelsheim, DE
Prosecution history
- 30 Jun 2022 — ABANDONMENT NOTICE E-MAILED - EXPRESS ABANDONMENT
- 30 Jun 2022 — ABANDONMENT - EXPRESS MAILED
- 29 Jun 2022 — TEAS EXPRESS ABANDONMENT RECEIVED
- 27 Jun 2022 — PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED
- 27 Jun 2022 — ASSIGNED TO LIE
- 14 Jun 2022 — TEAS VOLUNTARY AMENDMENT RECEIVED
- 27 May 2022 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
- 27 May 2022 — NEW APPLICATION ENTERED